4SC AG's Resminostat receives FDA Orphan Drug Status for Hodgkin's Lymphoma

PLANEGG-MARTINSRIED, Germany--(BUSINESS WIRE)--4SC AG (Frankfurt, Prime Standard: VSC), a discovery and development company of targeted small molecule drugs for autoimmune diseases and cancer, today announced that the US Food and Drug Administration (FDA) has granted orphan drug designation to 4SC's lead oncology compound resminostat in Hodgkin's lymphoma (HL). Resminostat was recently granted orphan drug designation by the FDA in another oncology indication, hepatocellular carcinoma (HCC).